Usefulness of Practitioner-Led Pancreatic Cancer Screening
Kazuya Matsumoto,
Yoshinori Kushiyama,
Akio Izumi,
Koji Ohnishi,
Masahiko Miura,
Yasufumi Ohuchi,
Ikuko Hori,
Tomonori Nakamura,
Kotaro Hori,
Kenji Koshino,
Junko Kobayashi,
Nagisa Yoshino,
Ushio Hoshino,
Takekiyo Okumura,
Takashi Tanimura,
Shinsuke Tanaka,
Shino Tanaka,
Tadashi Nabika,
Tatsuaki Nozu,
Yutaka Wakatsuki,
Syunsuke Katayama,
Shizue Yoshioka,
Kenichi Ito,
Akiko Uchida,
Noriji Yuhara,
Hisashi Noma,
Hajime Isomoto
Affiliations
Kazuya Matsumoto
Irisawa Medical Clinic, Matsue 690-0025, Japan
Yoshinori Kushiyama
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Akio Izumi
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Koji Ohnishi
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Masahiko Miura
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Yasufumi Ohuchi
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Ikuko Hori
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Tomonori Nakamura
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Kotaro Hori
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Kenji Koshino
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Junko Kobayashi
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Nagisa Yoshino
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Ushio Hoshino
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Takekiyo Okumura
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Takashi Tanimura
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Shinsuke Tanaka
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Shino Tanaka
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Tadashi Nabika
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Tatsuaki Nozu
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Yutaka Wakatsuki
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Syunsuke Katayama
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Shizue Yoshioka
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Kenichi Ito
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Akiko Uchida
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Noriji Yuhara
Pancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan
Hisashi Noma
Department of Data Science, The Institute of Statistical Mathematics, Tachikawa 190-8562, Japan
Hajime Isomoto
Division of Medicine and Clinical Science, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan
The 5-year survival rate for pancreatic cancer has improved (10%) but remains worse than that for other cancers. Early pancreatic cancer diagnosis is challenging, and delayed diagnosis can delay treatment, which impairs survival. Practitioners do not promptly refer cases to a general hospital, causing delayed discovery. Herein, we aimed to examine the usefulness of the Pancreatic Cancer Project in Matsue, whose objective is to detect pancreatic cancer in patients presenting at any medical institution in Matsue City. Clinical data were extracted from medical records, and abdominal ultrasonography and tumor marker blood level assessments were performed (n = 234; median age, 71 [range, 41–94] years; 51% male). Cases with abnormal abdominal ultrasonography or blood test findings were referred for specialist imaging and followed up. The pancreatic cancer detection rate was 6.0% (n = 14); all cases were referred to a general hospital by practitioners within 1 month. Patients had stage IA (n = 1), IIA (n = 6), IIB (n = 2), III (n = 1), and IV (n = 4) disease. Overall, pancreatic cancer could be detected at an earlier stage (I–II), but referral to a general hospital by visiting practitioners should be prompt. The Pancreatic Cancer Project in Matsue may help improve the detection and prognosis of pancreatic cancer.
